Csenge Advisory Group’s Ascendis Pharma A/S ASND Stock Holding History

Csenge Advisory Group’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$579K	Buy	2,171 +225	+12%	+$52.6K	0.02%	429
2026 Q1	$445K	Sell	1,946 -1,000	-34%	-$224K	0.02%	463
2025 Q4	$628K	Buy	+2,946	New	+$608K	0.03%	394

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Csenge Advisory Group's ASND Position: Q2 2026 in Review

Csenge Advisory Group increased its Ascendis Pharma A/S (ASND) stake by 12% in Q2 2026, buying an estimated $52.6K and bringing the position to 2,171 shares worth $579K. The position accounts for 0.02% of the portfolio, ranked #429.

Csenge Advisory Group first reported a position in ASND in Q4 2025 and has held it in 3 quarters since. The position peaked at $628K in Q4 2025. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Csenge Advisory Group held 2,171 shares of Ascendis Pharma A/S worth $579K as of Q2 2026.
Csenge Advisory Group bought 225 Ascendis Pharma A/S shares in Q2 2026, an estimated $52.6K.
Ascendis Pharma A/S made up 0.02% of Csenge Advisory Group's portfolio in Q2 2026, its #429 holding.
Csenge Advisory Group first reported a position in Ascendis Pharma A/S in Q4 2025 and has held it in 3 quarters since.
Csenge Advisory Group's Ascendis Pharma A/S position peaked at $628K in Q4 2025.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Csenge Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.